Anne F. Schott, MD
Advertisement
Articles by Anne F. Schott, MD
24 ARV-471, a PROTAC Estrogen Receptor (ER) Degrader in Advanced ER+/Human Epidermal Growth Factor Receptor 2 (HER2)– Breast Cancer: Phase 2 Expansion (VERITAC) of a Phase 1/2 Study
BySara A. Hurvitz, MD,Anne F. Schott, MD,Cynthia X. Ma, MD, PhD,Erika P. Hamilton, MD,Rita Nanda, MD,George Zahrah,Natasha Hunter, MD,Antoinette R. Tan,Melinda L. Telli, MD,Jesus Anampa Mesias,Rinath Jeselsohn,Pamela N. Munster, MD,Haolan Lu,Richard Gedrich,Cecile Mather,Janaki Parameswaran,Hyo S Han
This second edition of the text edited by Bland and Copeland represents a comprehensive reference that reviews the history, pathobiology, and current clinical management of diseases of the breast. Much more than a book about breast
Advertisement
Latest Updated Articles
- The Breast: Comprehensive Management of Benign and Malignant Diseases, Second Edition
Published: February 1st 2001 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Novel SSTR-Targeted Alpha Therapy Shows “Encouraging” Activity in GEP-NETs
2
Radiotherapy Plus Chemoimmunotherapy Improves Frontline ES-SCLC Prognosis
3
Pembrolizumab Combo Does Not Significantly Improve OS in Unresectable HCC
4
HER3-DXd Yields Activity in NSCLC, Breast Cancer Brain Metastasis Groups
5
